KRAS and cancer: Though KRAS codon 61 appeared as prognostic biomarker in stage III cancer, the rare event may indicate indeterminacy at present, considering the low codon 61 mutation frequency in CRC22, 27, confirmation of the prognostic value required further investigation with a larger sample size.